Use of evidence summaries to inform pharmacological treatment of people with suspected or diagnosed SARS-CoV-2 / COVID-19 respiratory infection
PDF (Español)


COVID-19, severe acute respiratory syndrome coronavirus 2, drug therapy, antivirals agents, SARS-CoV-2.

How to Cite

Yomayusa González N, Low Padilla E, de la Hoz Siegler I, Chacón K, Acevedo Peña J, Barrero Garzón L, Barrera Barinas A, Tolosa Pérez N, Castillo Niuman A, Guevara Pulido F, Castelblanco Cuevas D, Pinzón Flórez C, Mendivelso Duarte F, Cantor Cruz F, Castillo Gutiérrez A, Gómez Gómez O, Ávila A, Guevara C, Álvarez Moreno C, Rojas Gambasica J, Arbeláez Duque CM, García Guarín B, Cárdenas Rodríguez M, Robayo Rodríguez S, Torres Castro M. Use of evidence summaries to inform pharmacological treatment of people with suspected or diagnosed SARS-CoV-2 / COVID-19 respiratory infection. Rev. Colomb. Nefrol. [Internet]. 2020 Apr. 14 [cited 2024 Jul. 18];7(Supl.2). Available from:


Introduction: Due to the emergence of the SARS-CoV-2 coronavirus since December 2019, a large volume of scientific production has been generated, in some cases uncertain or controversial, especially in the pharmacological management of patients with this infection; therefore, it is considered a relevant search for methodological alternatives to carry out its rigorous, systematic and quality synthesis, but with less execution time and lower cost.

Objective: To present the available evidence regarding the pharmacological management of people with suspected or diagnosed respiratory SARS-CoV-2 (COVID-19) using the method of rapid systematic reviews (RS-R) in potentially effective drugs for their management.

Methodology: A systematic and structured search was conducted in Medline, Embase, Scopus, Cochrane Library, Clinical trials and Google Scholar in English. Studies included clinical practice guidelines, consensus, systematic reviews, meta-analyses, clinical trials, and other primary studies. Data search and extraction were performed by multiple reviewers, but none were paired.

Results: Sixteen questions of clinical interest were resolved, related to the use in COVID-19 of lopinavir/ritonavir, nelfinavir, oseltamivir, remdesivir, ribavirin, teicoplanin, umifenovir, favipiravir, tocilizumab, ivermectin, convalescent plasma; the use of support management drugs such as dexamethasone were also evaluated, as well as the concomitant use of drugs that generated doubts, such as NSAIDs, ACEis, and ARA IIs.

Conclusions: Summaries of evidence are within the pandemic scenario as a good methodological alternative to offer quality information in the short term for decision-makers.
PDF (Español)


Munn Z, Lockwood C, Moola S. The Development and Use of Evidence Summaries for Point of Care Information Systems: A Streamlined Rapid Review Approach. Worldviews Evid Based Nurs. 2015;12(3):131-38. Available from:

Andermann A, Pang T, Newton JN, Davis A, Panisset U. Evidence for Health II: Overcoming barriers to using evidence in policy and practice. Heal Res Policy Syst. 2016;14(17): Available from:

Patnode CD, Eder ML, Walsh ES, Viswanathan M, Lin JS. The Use of Rapid Review Methods for the U.S. Preventive Services Task Force. Am J Prev Med. 2018;54(1S1):S19-25. Available from:

Tricco AC, Langlois E V, Straus SE. World Health Organization, Alliance for Health Policy and Systems Research. Rapid Reviews To Strengthen Health Policy and Systems: a Practical Guide [Internet]. 2017. Available from: publications/rapid-review-guide/en/

Gutierrez I. Protocolos de búsqueda bibliográfica. Vitoria-Gasteiz [Internet]. España; 2002. Available from: https://www.osakidetza.euskadi. eus/contenidos/informacion/osteba_formacion_/es_def/adjuntos bibliografia.pdf

Dobbins M. Rapid Review Guidebook. Steps for conducting a rapid review [Internet]. Canada: National Collaborating Centre for Methods and Tools; 2017. 25 p. Available from:

Lehoux P, Tailliez S, Denis JL, Hivon M. Redefining health technology assessment in Canada: Diversification of products and contextualization of findings. Int J Technol Assess Health Care. 2004;20(3):325-36. Available from:

Keralty. Instituto Global de Excelencia Clínica. Manual de revisiones sistemáticas rápidas. Colombia; 2019. 9. Agencia Española de Medicamentos y Productos Sanitarios. La AEMPS informa que ningún dato indica que el ibuprofeno agrave las infecciones por COVID-19 [Internet]. 2020. p. 1. Available from: medicamentosusohumano-3/2020-medicamentosusohumano-3/la-aemps-informa-que-ningun-dato-indica-que-el-ibuprofeno-agrave-las-infecciones-por-covid-19/

Little P, Moore M, Kelly J, Williamson I, Leydon G, McDermott L, et al. Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial. BMJ. 2013;347(f6041). Available from:

Basille D, Plouvier N, Trouve C, Duhaut P, Andrejak C, Jounieaux V. Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study. Lung. 2017;195(2):201-8. Available from:–1

Organización Mundial de la Salud (OMS). The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 [Internet]. 2020 [cited 2020 Jul 29]. Available from: anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19

National Institutes for Clinical Excellence (NICE) [Internet]. 2020 [cited 2020 Jul 30]. Available from:

Yousefifard M, Zali A, Zarghi A, Madani Neishaboori A, Hosseini M SS. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence. Int J Clin Pr [Internet]. 2020;e13557. Available from:

Sodhi M, Khosrow-Khavar F, FitzGerald JM EM. Non-Steroidal Anti-Inflammatory Drugs and the Risk of Pneumonia Complications: A Systematic Review. Pharmacotherapy [Internet]. 2020. Available from:

American College of Cardiology. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 [Internet]. 2020. Available from: 2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns- re-using-raas-antagonists-in-covid-19

European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers [Internet]. 2020. Available from: Council-on-Hypertension-(CHT)/News/position-statement- of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. Available from:

Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020; 525(1):135-140. Available from:

Schneider M, Ackermann K, Stuart M, Wex C, Protzer U, Schätzl HM, et al. Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain. J Virol. 2012;86(18):10112-22. Available from:

Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59. Available from:

Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Dexamethasone for COVID-19-Preliminary Report Effect of Dexamethasone in Hospitalized Patients with COVID-19 - Preliminary Report. medRxiv Internet]. 2020. Available from: https://

RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med [Internet]. 2020; Available from: NEJMoa2021436?articleTools=true

National Institutes of Health. Corticosteroids | Coronavirus Disease COVID-19 [Internet]. [cited 2020 Jul 11]. Available from:

Organización Mundial de la Salud. Preguntas y respuestas sobre la dexametasona y la COVID-19 [Internet]. [cited 2020 Jul 11]. Available from:

Institut national d’excellence en santé et en services sociaux (INESSS). COVID-19 et dexaméthasone [Internet]. 2020 [cited 2020 Jul 11]. p. 1-39. Available from:

Search of: dexamethasone | covid-19 - List Results - [Internet]. [cited 2020 Jul 17]. Available from:

Johnson DB, Lopez MJ KB. Dexamethasone - StatPearls - NCBI Bookshelf [Internet]. [cited 2020 Aug 1]. Available from:

Polderman JAW, Farhang-Razi V, van Dieren S, Kranke P, DeVries JH, Hollmann MW, et al. Adverse side-effects of dexamethasone in surgical patients – an abridged Cochrane systematic review. Anaesthesia. 2019;74(7):929-39. Available from:

Ferner R, DeVito N. AJ. Dexamethasone. Centre for Evidence-Based Medicine. Oxford University [Internet]. [cited 2020 Jul 11]. Available from:

Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc. 2020;23(4):1-9. Available from:

Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ. 2020;192(27):E734-44. Available from:

Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs. 1998;56(1):147-67. Available from:

Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS- associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719-25. Available from:

Agencia Española de Medicamentos y Productos Sanitarios. Oseltamivir. Ficha técnica. [Internet]. Available from:

Li H, Wang YM, Xu JY, Cao B. [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E002. Available from: A Prospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. NCT0425501. Available from:

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med. 2020. Available from:

Wang Y, Zhang D, Du PG, Du PR, Zhao PJ, Jin PY, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78. Available from:

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid- 19. N Engl J Med. 2020;NEJMoa2015301. Available from: 10.1056/NEJMoa2015301

Food and Drug Administration. FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF VEKLURY® (remdesivir) [Internet]. [cited 2020 Aug 1]. Available from:

European Medicines Agency. First COVID-19 treatment recommended for EU authorisation [Internet]. [cited 2020 Aug 1]. Available from:

National Institutes of Health. Remdesivir | Coronavirus Disease COVID-19 [Internet]. [cited 2020 Jul 27]. Available from:

National Institute for Health and Care Excellence. Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 [Internet]. [cited 2020 Aug 1]. Available from:

Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. Available from:

Elfiky A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020;253:117592 Available from: Ribavirin [Internet]. Available from: Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/ lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem. 2016;291(17):9218-32. Available from:

Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020;55(4):105944. Available from:

Balzarini J, Keyaerts E, Vijgen L, Egberink H, De Clercq E, Van Ranst M, et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res. 2006;72(1):20-33. Available from:

Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020. Available from:

Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, et al. Advances in respiratory virus therapeutics – A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45-67. Available from:

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60. Available from:

Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64-8. Available from:

Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1-e5. Available from:

Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Med Virol. 2020;10.1002/jmv.26256. Available from:

Du YX CX. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. Clin Pharmacol Ther. 2020;108(2):242-47. Available from:

Agenzia Italiana del Farmaco. AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull’efficacia [Internet]. 2020 [cited 2020 Apr 19]. Available from: per-covid-19-non-autorizzato-in-europa-e-usa-scarse-evidenze-scientifiche-sull-efficacia

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020; Mar 18. Available from:

Chang Chen, Yi Zhang, Jianying Huang, Ping Yin, Zhenshun Cheng, Jianyuan Wu et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv Prepr [Internet]. 2020. Available from: Favipiravir [Internet]. 2020 [cited 2020 Jul 27]. Available from:

Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS SF. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. J Med Virol [Internet]. 2020;10.1002/jmv.26038. Available from:

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev [Internet]. 2020;19(7). Available from:

Sciascia, S., Aprà, F., Baffa, A., Baldovino, S., Boaro, D., Boero R. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020;38(3):529-32

Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med. 2020;76:36-42. Available from:

Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2020. Available from:

Panamerican Health Organization. PAHO. Ongoing living update of potential COVID-19 therapeutics: summary of rapid systematic reviews [Internet]. 2020 [cited 2020 Jun 18]. Available from:

Patel Amit DS. Ivermectin in COVID-19 Related Critical Illness [Internet]. 2020 [cited 2020 Apr 6]. Available from:

Patel A. Usefulness of Ivermectin in COVID-19 Illness [Internet]. 2020 [cited 2020 Apr 19]. Available from:

Panamerican Health Organization. Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews [Internet]. 2020 [cited 2020 Apr 28]. Available from: bitstream/handle/10665.2/52025/PAHOIMSCovid19200008_eng.pdf?sequence=1&isAllowed=y

Bray, M., Rayner, C., Noël, F., Jans, D., & Wagstaff K. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res [Internet]. 2020;104805. Available from:

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res [Internet]. 2020;104787. Available from:

Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin ?/?1 heterodimer. Antiviral Res. 2020.

Schmith, V. D., Zhou, J. J., & Lohmer LR. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther [Internet]. 2020;10.1002/cpt.1889. Available from:

Pimenoff VN, Elfstrom M, Dillner J. A systematic review of convalescent plasma treatment for COVID19. medRxiv. 2020. Available from:

Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, Lamikanra A, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020;5(5):CD013600. Available from:

Instituto de Efectividad Clínica y Sanitaria. Plasma de convalecientes en COVID-19 [Internet]. Argentina; 2020 [cited 2020 May 25]. Available from:

INESSS. COVID-19 et thérapie passive par anticorps (plasma convalescent) [Internet]. 2020 [cited 2020 May 24]. p. 1-14. Available from:

Health Technology Wales. Plasmapheresis of convalescent plasma to confer passive immunity [Internet]. 2020 [cited 2020 May 26]. p. 1-10. Available from:

Canadian Agency for Drugs and Technologies in Health (CADTH). Convalescent Plasma Therapy for the Treatment of COVID-19: Clinical Effectiveness [Internet]. 2020 [cited 2020 May 23]. p. 1-14. Available from: Convalescent Plasma COVID.pdf

Agency for Care and Effectiveness and Ministry of Health Singapore. Should convalescent plasma be used for COVID-19? [Internet]. 2020 [cited 2020 May 22]. p. 1-6. Available from: docs/librariesprovider5/clinical-evidence-summaries/convalescent-plasma-infusion-for-covid-19-(updated-18-may-2020).pdf

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.




Download data is not yet available.